HOW TRANSPARENT IS NH? FOLLOW OUR SCORECARD

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

3.645 +0.135 (+3.85%)
Delayed Quote Updated: 12:57 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
5 Revealing Analyst Questions From GoodRx’s Q3 Earnings Call
GoodRx’s third quarter results were met with a moderate positive market response, as the company’s revenue modestly exceeded Wall Street expectations despite being flat year-over-year. Management... 
Via StockStory
Topics Earnings
News headline image
3 Value Stocks We Find Risky
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
3 Low-Volatility Stocks with Open Questions
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
GoodRx Stock Buzzes As TrumpRx Drug Pricing Shake-Up Draws BofA Warning On Core Business Model ↗
Via Stocktwits
News headline image
GDRX Q3 Deep Dive: Manufacturer Solutions Growth Offsets Flat Prescription Volumes
Healthcare tech company GoodRx (NASDAQ:GDRX) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $196 million. Its non-GAAP profit of $0.08 per share... 
Via StockStory
News headline image
GoodRx’s (NASDAQ:GDRX) Q3 Sales Top Estimates
Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $196 million. Its non-GAAP profit of $0.08 per... 
Via StockStory
News headline image
GoodRx Reports Third Quarter 2025 Results
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
GoodRx (GDRX) Q3 Earnings Report Preview: What To Look For
Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting earnings this Tuesday after market close. Here’s what to expect. 
Via StockStory
News headline image
Healthcare Technology Stocks Q2 Highlights: Tandem Diabetes (NASDAQ:TNDM)
Looking back on healthcare technology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Tandem Diabetes (NASDAQ:TNDM) and its peers. 
Via StockStory
News headline image
Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying' ↗
Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative "a good start," while still acknowledging... 
Via Benzinga
Topics Government
News headline image
GoodRx (GDRX): Buy, Sell, or Hold Post Q2 Earnings?
Over the past six months, GoodRx’s stock price fell to $3.94. Shareholders have lost 9.8% of their capital, which is disappointing considering the S&P 500 has climbed by 30.6%. This was partly due to... 
Via StockStory
Topics Stocks Supply Chain
News headline image
GoodRx Launches New Hair Loss Subscription for Men to Simplify Access to Affordable Treatment
From GoodRx
Via Business Wire
News headline image
3 Cash-Producing Stocks with Warning Signs
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Tandem Diabetes, agilon health, GoodRx, Neogen, and Fortrea Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers. 
Via Benzinga
Topics Government
News headline image
GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
Q2 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare technology industry, including GoodRx (NASDAQ:GDRX) and its peers. 
Via StockStory
News headline image
Amgen To Sell Cholesterol Drug For Approximately 60% Discount ↗
Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow. 
Via Stocktwits
Topics Government
News headline image
GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings
From GoodRx
Via Business Wire
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks
News headline image
Why GoodRx (GDRX) Stock Is Up Today
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 1.4% in the afternoon session after the stock's positive momentum continued following a potential partnership with TrumpRx and an expanded... 
Via StockStory
Topics World Trade
News headline image
GoodRx Launches Brand Medication Savings Program at National Retail Pharmacy
From GoodRx
Via Business Wire
News headline image
Clover Health, GoodRx, Cardinal Health, McKesson, and Humana Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential... 
Via StockStory
Topics World Trade
News headline image
2 of Wall Street’s Favorite Stocks Worth Investigating and 1 Facing Headwinds
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
Why GoodRx (GDRX) Shares Are Sliding Today
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) fell 4.9% in the afternoon session after a report on the U.S. job market raised concerns about a potential recession. 
Via StockStory
Topics Economy Initial Public Offering Stocks
News headline image
GoodRx Saddles Up With “The Savings Wrangler,” a Bold New Brand Campaign to Tame the Wild West of Prescription Pricing
From GoodRx
Via Business Wire
News headline image
Why GoodRx (GDRX) Stock Is Up Today
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 3.1% in the morning session after investor enthusiasm continued following its recent partnership with Danish pharmaceutical giant Novo... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
News headline image
GoodRx (GDRX) Stock Is Up, What You Need To Know
Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 3.7% in the afternoon session after investor enthusiasm continued following its recent partnership with Danish pharmaceutical giant Novo... 
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers ↗
Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses. 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article